
    
      directSTIM DBS Therapy for Movement Disorders is indicated for patients with disabling tremor
      or symptoms of Parkinson's disease.

      Subjects selected to participate in the study will be Parkinson's Disease (PD) patients who
      are eligible for bilateral DBS for STN therapy and meet the inclusion criteria and none of
      the exclusion criteria.

      Primary safety and effectiveness endpoints data will be collected through 6 months of
      follow-up. The values used for comparison are derived from a review of literature spanning
      from 2001 to 2019.

      After completing the 6 month follow-up, subject will exit the study, and continue to be
      followed by their physician per usual care.
    
  